Webcast: Preventing and Treating Influenza in the Age of COVID-19: How to Avoid a “Twindemic” Effect

The potential impacts of influenza coupled with those of COVID-19 have been termed as a potential “twindemic” coming for the US healthcare system. Although this early concern did not materialize, clinicians should pay attention to the diagnosis and management of influenza in the COVID-19 era and beyond, particularly in adults with multiple chronic comorbidities, including cardiovascular disease, obesity, diabetes, asthma and COPD.

During this webinar, experts will discuss practical strategies for improving the prevention and treatment of influenza, including a review of the efficacy and safety of immunizations and antivirals to prevent influenza complications in this setting.

Target Audience

This activity is designed for US-based healthcare professionals, including cardiologists, endocrinologists, primary care clinicians (PCPs), nurse practioners, nurses, pharmacists, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize influenza vaccine recommendations and the efficacy and safety of influenza vaccines across the age spectrum
  • List practical steps and strategies to maintain influenza immunization schedules amidst COVID-19 challenges
  • Interpret influenza screening and testing guidance in the COVID-19 era
  • Develop approaches to optimize the early treatment of influenza in the COVID-19 era based on the efficacy and safety of established and newer antivirals, as well as current recommendations
Course summary
Available credit: 
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 Participation
Course opens: 
Course expires: 

Gregory A. Poland, MD, MACP, FRCP (London)
Mary Lowell Leary Emeritus Professor of Medicine
Distinguished Investigator, Mayo Clinic
Director, Mayo Vaccine Research Group
Editor-in-Chief, VACCINE
Mayo Clinic
Rochester, MN

Dr. Poland discloses the following: 

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being doncudted by Merck Research laboratories. Dr. Poland offers consultiative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergen Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Johnson & Johnson/Janssen Global Services LLC, Kentucky Bioprocessing,  AstraZeneca, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia and measles peptide vaccines.  Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayer Clinic Conflict of Interest Review Board and are conducted in complaince with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in complaince with Mayo Clinic Conflict of Interest policies.


Michael G. Ison, MD MS FIDSA FAST
Division of Infectious Diseases & Organ Transplantation
Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Feinberg School of Medicine
Chicago, IL

Dr. Ison discloses the following:

Research Support (Paid to Northwestern University):  AiCuris, Janssen, Shire
Paid Consultation (Paid to Michael Ison): Adagio, AlloVir, Celltrion, Cidara, Genentech/Roche, Janssen, Shionogi, Takeda, Viracor Eurofins
Unpaid Consultation: Romark
Data and Safety Monitoring Board Participation: NIH, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda, Vitaeris

1.5 hour

This activity is supported by an educational grant from Biocryst Pharmaceuticals, Inc.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Medical Education (TME). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2717-H06-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period May 4, 2021 through May 4, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.